2020 News Releases
First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
Osaka, JAPAN and King of Prussia, Pa., USA • The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is und…
UQ, CEPI and CSL partner for COVID-19
• CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate • …
Development of COVID-19 immunoglobulin commences
Plasma-derived therapeutic with potential to treat serious complications of COVID-19.